Eli Lil­ly ush­ers up-and-com­ing GIP/GLP-1 drug in­to PhI­II as No­vo Nordisk ri­val wows with im­pres­sive re­sults

With No­vo Nordisk’s GLP-1 drug Ozem­pic (semaglu­tide) on its tail, Eli Lil­ly has round­ed up some mid-stage da­ta to show it has the right can­di­date to fol­low on Trulic­i­ty’s block­buster suc­cess in the com­pet­i­tive di­a­betes mar­ket.

In­ves­ti­ga­tors re­port that LY3298176, a dual GIP and GLP-1 re­cep­tor ag­o­nist, out­per­formed both place­bo and Trulic­i­ty (du­laglu­tide) in terms of blood sug­ar re­duc­tion and weight loss for pat­ints with type 2 di­a­betes. And while cross-tri­al com­par­isons al­ways war­rant cau­tion, the drug ap­pears to of­fer a siz­able ad­di­tion­al ef­fect over GLP monother­a­pies.

Like GLP-1, GIP is an in­cretin hor­mone tied to in­sulin se­cre­tion.

“This drug is set­ting up to be per­haps the most crit­i­cal part of LLY’s di­a­betes strat­e­gy go­ing fwd … es­pe­cial­ly in the face of No­vo’s new launch­es,” Ever­core ISI an­a­lyst Umer Raf­fat writes in a note.

In­vestors were pay­ing close at­ten­tion. Lil­ly’s stock $LLY shot up 4%, a big deal for big-cap com­pa­ny, while No­vo’s shares $NVO slid 7%.

On the pri­ma­ry ef­fi­ca­cy mea­sure — change in HbA1c from base­line to 26 weeks — 90% of those who re­ceived the 10 mg dose of LY3298176 achieved the rec­om­mend­ed HbA1c tar­get of 7% of less; the 5 mg group record 69.1% and the 15 mg group, 77.4%. Mean­while, the sin­gle du­laglu­tide and place­bo arms had 52% and 12% of pa­tients hit­ting that tar­get.

Of note, the 15 mg group ac­tu­al­ly saw a high­er per­cent­age (30%) of pa­tients achiev­ing the most im­pres­sive re­duc­tion, which is HbA1c lev­els of less than 5.7% — what you’d ex­pect to see in non-di­a­bet­ics. Among those on the 10 mg dose, 18% got to that point.

But where LY3298176 re­al­ly stood out was in the weight loss num­bers: -4.8 kg (5 mg), -8.7 kg (10 mg) and -11.3 kg (15 mg) while pa­tients on du­laglu­tide shed an av­er­age of -2.7 kg. That trans­lates to more than a third of drug arm pa­tients los­ing 10% or more of their base­line body weight.

Source: Umer Raf­fat

Click on the im­age to see the full-sized ver­sion

Re­searchers are al­so hap­py with the safe­ty pro­file, which they say is “sim­i­lar to the GLP-1 RA class” with the most com­mon­ly re­port­ed side ef­fects be­ing nau­sea, di­ar­rhea and vom­it­ing.

“We set a high bar for this Phase II study, and the re­sults ex­ceed­ed our ex­pec­ta­tions,” said Jeff Em­mick, vice pres­i­dent of prod­uct de­vel­op­ment, Lil­ly Di­a­betes. “We’re ex­cit­ed to con­tin­ue study­ing GIP/GLP-1 RA and hope to add it to our wide range of ther­a­pies for peo­ple with di­a­betes.”

It’s now time to move in­to a larg­er Phase III tri­al dubbed SUR­PASS, which Lil­ly plans to ini­ti­ate by ear­ly 2019 and com­plete in late 2021.

If the da­ta trends hold up — as Raf­fat is bull­ish it would — he sees the drug tak­ing a key po­si­tion in a bi­fur­cat­ing GLP-1 mar­ket:

  • oral se­ma will take lots of share from short-act­ing GLP-1s (where No­vo is al­ready pulling spend from Vic­toza) as well from orals
  • per­haps there will re­main a long-act­ing niche … with No­vo’s Ozem­pic and LLY’s Trulic­i­ty … LLY will like­ly shift the spend away from Trulic­i­ty and over to this GIP/GLP.

In his­toric Covid-19 ad­comm, vac­cine ex­perts de­bate a sea of ques­tions — but of­fer no clear an­swers

The most widely anticipated and perhaps most widely watched meeting in the FDA’s 113-year history ended late Thursday night with a score of questions and very few answers.

For nearly 9 hours, 18 different outside experts listened to public health agencies and foundations present how the United States’ Covid-19 vaccine program developed through October, and they debated where it should go from there: Were companies testing the right metrics in their massive trials? How long should they track patients before declaring a vaccine safe or effective? Should a vaccine, once authorized, be given to the volunteers in the placebo arm of a trial?

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.

A top drug pro­gram at Bay­er clears a high bar for CKD — open­ing the door to an FDA pitch

Over the past 4 years, Bayer has been steering a major trial through a pivotal program to see if their drug finerenone could slow down the pace of chronic kidney disease in patients suffering from both CKD as well as Type 2 diabetes.

Today, their team jumped on a virtual meeting hosted by the American Society of Nephrology to offer a solid set of pivotal data to demonstrate that the drug can delay dialysis or a kidney replacement as well as cardio disease, while also adding some worrying signs of hyperkalemia among the patients taking the drug. And they’re hustling it straight to regulators in search of an approval for kidney disease and cardio patients — one of the toughest challenges in the book, as demonstrated by repeated past failures.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.

Michel Vounatsos, Biogen CEO (via YouTube)

UP­DAT­ED: Bio­gen spot­lights a pair of painful pipeline set­backs as ad­u­canum­ab show­down looms at the FDA

Biogen has flagged a pair of setbacks in the pipeline, spotlighting the final failure for a one-time top MS prospect while scrapping a gene therapy for SMA after the IND was put on hold due to toxicity.

Both failures will raise the stakes even higher on aducanumab, the Alzheimer’s drug that Biogen is betting the ranch on, determined to pursue an FDA OK despite significant skepticism they can make it with mixed results and a reliance on post hoc data mining. And the failures are being reported as Biogen was forced to cut its profit forecast for 2020 as a generic rival started to erode their big franchise drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.

Biond­Vax stock im­plodes af­ter a big PhI­II gam­ble for its uni­ver­sal flu vac­cine fails

After flying high on Wall Street for the last few months of a pandemic, BiondVax’s stock and dreams of getting approval for its universal flu vaccine hit the windshield.

The Jerusalem-based biotech announced on Friday that its only clinical candidate, M-001, failed both primary and secondary endpoints in a Phase III study. There was no statistically significant difference in reduction of flu illness and severity between the vaccine and placebo groups, according to the company. The vaccine did prove safe, if ineffective, BiondVax said.

Pascal Soriot, AstraZeneca CEO (Zach Gibson/Bloomberg via Getty Images)

UP­DAT­ED: FDA gives As­traZeneca the thumbs-up to restart PhI­II Covid-19 vac­cine tri­als, and J&J is prepar­ing to re­sume its study

Several countries had restarted their portions of AstraZeneca’s global Phase III Covid-19 vaccine trial after the study was paused worldwide in early September, but the US notably stayed on the sidelines — until now. Friday afternoon the pharma giant announced the all clear from US regulators. And on top of that, J&J announced Friday evening that it’s preparing to resume its own Phase III vaccine trial.

Ul­tragenyx in­jects $40M to grab Solid's mi­crody­s­trophin trans­gene — while side­step­ping the AAV9 vec­tor that stirred up safe­ty fears

Since before Ilan Ganot started Solid Bio to develop a gene therapy for kids like his son, who has Duchenne muscular dystrophy, Ultragenyx CEO Emil Kakkis has been watching and advising the former investment banker as he navigated the deep waters of drug development.

Just as Solid is getting back up on its feet after a yearlong clinical hold, Kakkis has decided to jump in for a formal alliance.

With a $40 million upfront, Ultragenyx is grabbing 14.45% of Solid’s shares $SLDB and the rights to its microdystrophin construct for use in combination with AAV8 vectors. Solid’s lead program, which utilizes AAV9, remains unaffected. The company also retains rights to other applications of its transgene.

Adam Koppel and Jeffrey Schwartz, Bain

Bain ex­ecs Adam Kop­pel and Jef­frey Schwartz line up $125M for their first blank check deal as Wall Street con­tin­ues to em­brace biotech

Adam Koppel and Jeffrey Schwartz have jumped into the blank check game, raising $125 million for a stock listing in search of a company.

Their SPAC, BCLS Acquisition Corp, raised $125 million this week, with a line on $25 million more as it scouts for a biotech in search of money and a place on Wall Street.

The two principals at Bain Life Sciences have been on a romp since they set up the Bain operation 4 years ago. Their S-1 spells out a track record of 22 deals totaling $650 million for the life sciences group, which led to 9 IPOs.

Covid-19 roundup: An mR­NA play­er gets a boost out of the lat­est round of an­i­mal da­ta; Phase­Bio pulls the plug on treat­ment tri­al

The big tell for CureVac $CVAC is coming up with a looming early-stage readout on their mRNA Covid-19 vaccine in the clinic. But for now they’ll make do with an upbeat assessment on the preclinical animal data they used to get into the clinic.

Researchers for the German biotech say they got the high antibody titers and T cell activation they were looking for, lining up a hamster challenge to demonstrate — in a simple model — that the vaccine could protect the furry creatures. Like the other mRNA vaccines, the drug sends instructions to spur cells to decorate themselves with the distinctive spike on the virus to elicit an immune response.

Stephen Hahn, FDA commissioner (AP Images)

As FDA sets the stage for the first Covid-19 vac­cine EUAs, some big play­ers are ask­ing for a tweak of the guide­lines

Setting the stage for an extraordinary one-day meeting of the Vaccines and Related Biological Products Advisory Committee this Thursday, the FDA has cleared 2 experts of financial conflicts to help beef up the committee. And regulators went on to specify the safety, efficacy and CMC input they’re looking for on EUAs, before they move on to the full BLA approval process.

All of this has already been spelled out to the developers. But the devil is in the details, and it’s clear from the first round of posted responses that some of the top players — including J&J and Pfizer — would like some adjustments and added feedback. And on Thursday, the experts can offer their own thoughts on shaping the first OKs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.